Tuesday, June 3, 2025

Aignostics & Mayo Clinic Unveil Pathology Model Results

Related stories

EXL & Databricks launch GenAI tool for code migration

EXL, a leading data and AI-driven company, has deepened...

Aptean Acquisition of VLEX for DACH ERP Reach

Aptean Inc., a global leader in AI-powered enterprise resource...

Portless Raises $18M to Transform Global E-Com & Fulfillment

Portless, a U.S.-based innovator in global e-commerce fulfillment, announced...

Syneris Launches to Disrupt AI with Decentralized Compute

A unified network leveraging underused GPU and CPU resources...

Tenable to Acquire Apex Security to Boost AI Risk Coverage

Tenable Holdings, Inc., the exposure management company, announced its intent...
spot_imgspot_img

Aignostics announced research results for a new pathology foundation model developed in collaboration with Mayo Clinic Digital Pathology. The model, built in two months using 1.2 million diverse slide images from Mayo Clinic and Charité – Universitätsmedizin Berlin, establishes a new state-of-the-art for performance across more than twenty public benchmarks. In addition, the model is computationally efficient, enhancing its usability relative to existing image-based models. High performance and efficiency were enabled by Aignostics’ pathologist-curated development approach, which emphasizes the integration of expert medical knowledge throughout the model development process.

“These results represent an exciting achievement in our collaboration with Mayo Clinic,” said Maximilian Alber, CTO of Aignostics. “Aignostics and Mayo Clinic have direct access to millions of additional training images and new data modalities that will be integrated into the model over time, further enhancing its capabilities and accuracy.”

Also Read: Innovaccer Raises $275M in Series F for Healthcare Cloud Expansion

Healthcare and life sciences organizations will be able to use the new model for research and clinical development. Aignostics will also integrate the model into its expanding portfolio of AI-powered pathology products, enabling accurate, generalizable solutions for biomarker, cell, and tissue image analysis. This dual approach – direct licensing of foundational technology and offering purpose-built applications – will allow partner organizations to leverage the model’s capabilities in ways that best suit their specific needs.

“Mayo Clinic Digital Pathology will work with Aignostics to transform pathology for the benefit of patients everywhere,” said Jim Rogers, CEO, Mayo Clinic Digital Pathology. “These results show there is real potential in combining Mayo Clinic’s vast medical expertise and resources with Aignostics’ pioneering technologies,” added Viktor Matyas, CEO of Aignostics. “They underline our ambition and readiness to jointly lead in this space.”

Source: PRNewswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img